There are currently 2781 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226
Recruiting
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cancer
Register for Updates
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
NCT04336722
Recruiting
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.
Gender:
All
Ages:
111 days and below
Trial Updated:
05/27/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Biliary Atresia
Register for Updates
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
NCT05646576
Recruiting
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: Palliative care (PEACE) plus usual oncology care Usual care (standard on... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma
Register for Updates
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT03319901
Recruiting
This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: Venetoclax Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Leukemia
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/26/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Neoplasms
Register for Updates
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
NCT05711615
Recruiting
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certai... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/25/2024
Locations: Dana-Farber - Harvard Cancer Center LAO, Boston, Massachusetts +1 locations
Conditions: Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Leiomyosarcoma, Unresectable Sarcoma, Unresectable Soft Tissue Sarcoma
Register for Updates
An Open-Label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease
NCT05757141
Recruiting
ABBV-CLS-7262 is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult and pediatric subjects. This is a 96-week, open-label, multiple cohort study enrolling adults and pediatric subjects with Vanishing White Matter disease who are 6 years or older. Subjects will attend regular visits during the course of the study and complete medical assessments, blood tests, checking for side effects, and completing questionnaires.
Gender:
All
Ages:
6 years and above
Trial Updated:
05/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Vanishing White Matter Disease
Register for Updates
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NCT06034327
Recruiting
This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy. This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.
Gender:
All
Ages:
Between 6 years and 8 years
Trial Updated:
05/24/2024
Locations: New England College of Optometry, Boston, Massachusetts
Conditions: Myopia, Juvenile Myopia, Myopia Progression
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Register for Updates
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
NCT05931276
Recruiting
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainab... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: End-Stage Kidney Disease, End-Stage Renal Disease
Register for Updates
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847
Recruiting
The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.
Gender:
All
Ages:
All
Trial Updated:
05/24/2024
Locations: Beth Israe Deaconess Medical Center, Boston, Massachusetts
Conditions: Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia
Register for Updates
Colorectal Cancer Screening in Cystic Fibrosis
NCT05362344
Recruiting
This multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer screening with colonoscopy. The primary endpoint is detection of any adenomas, including advanced adenomas and colorectal cancer (CRC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Cystic Fibrosis, Colorectal Cancer, Adenoma
Register for Updates